Ligand id: 8270

Name: cenersen

Structure and Physico-chemical Properties

2D Structure
No information available.
Summary of Clinical Use
Cenersen has been granted orphan drug designation by the EMA and FDA for the treament of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). The FDA also includes treatment of stage IIB-IV melanoma in its orphan designation. Cenersen has not progressed beyond Phase II clinical trial, with 2 out of 3 trials being withdrawn or terminated early.
Mechanism Of Action and Pharmacodynamic Effects
In some types of cancer cells the p53 apoptitic pathway malfunctions, such that activated p53 acts as a pro-survival signal for tumourigenically damaged cells. Cenersen blocks the translation of wild type and mutant p53 proteins, so cells can undergo cell death via p53-independent mechanisms of apoptosis. It is expected that this may sensitize cancer cells to standard chemotherapy.